Zhao Yuechen, Li Yanqing, Zhang Ruifeng, Wang Feng, Wang Tiejun, Jiao Yan
Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun, People's Republic of China.
Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, People's Republic of China.
Onco Targets Ther. 2020 Jun 11;13:5429-5441. doi: 10.2147/OTT.S254995. eCollection 2020.
Erastin was initially discovered as a small molecule compound that selectively kills tumor cells expressing ST and RAS and was later widely investigated as an inducer of ferroptosis. Ferroptosis is a recently discovered form of cell death caused by peroxidation induced by the accumulation of intracellular lipid reactive oxygen species (L-ROS) in an iron-dependent manner. Erastin can mediate ferroptosis through a variety of molecules including the cystine-glutamate transport receptor (system X ), the voltage-dependent anion channel (VDAC), and p53. Erastin is able to enhance the sensitivity of chemotherapy and radiotherapy, suggesting a promising future in cancer therapy. We hope that this review will help to better understand the role of erastin in ferroptosis and lay the foundation for further research and the development of erastin-based cancer therapies in the future.
艾拉司丁最初被发现是一种小分子化合物，它能选择性杀死表达ST和RAS的肿瘤细胞，后来作为铁死亡诱导剂被广泛研究。铁死亡是最近发现的一种细胞死亡形式，由细胞内脂质活性氧（L-ROS）以铁依赖的方式积累诱导的过氧化作用引起。艾拉司丁可通过多种分子介导铁死亡，包括胱氨酸-谷氨酸转运受体（系统Xc）、电压依赖性阴离子通道（VDAC）和p53。艾拉司丁能够增强化疗和放疗的敏感性，这表明其在癌症治疗方面具有广阔前景。我们希望这篇综述将有助于更好地理解艾拉司丁在铁死亡中的作用，并为未来进一步研究以及基于艾拉司丁的癌症治疗开发奠定基础。
